Kaye S B, Wanders J, Clavel M, Verweij J, Piccart M J, Smyth J F, Ten Bokkel Huinink W W, Wagener D J, Judson I R, Cavalli F
Beatson Oncology Centre, Western Infirmary, Glasgow.
Ann Oncol. 1992 May;3(5):406-8. doi: 10.1093/oxfordjournals.annonc.a058220.
A total of 91 eligible patients with metastatic cancer have been treated in a series of phase II trials of the novel pentacyclic pyrroloquinone, fosquidone. Tumour types were breast (24), ovary (25), head and neck (21) and melanoma (21). All patients, except those with melanoma had received prior chemotherapy. The drug was given intravenously as a 20 min infusion, at the dose of 120 mg/m2 on days 1 to 5 of a 3 week cycle. Treatment was well tolerated; the only significant side-effects being mild headaches and generalised musculo-skeletal pains. Response was assessed after 2 cycles of therapy. Only one patient (with head and neck cancer) achieved an objective partial response, lasting 6 weeks. A total of 12 patients demonstrated stable disease for a median duration of 15 to 20 weeks. Using this schedule of administration, fosquidone has no significant antitumour activity in this group of tumours.
在一系列关于新型五环吡咯并醌类药物磷喹酮的II期试验中，共有91例符合条件的转移性癌症患者接受了治疗。肿瘤类型包括乳腺癌（24例）、卵巢癌（25例）、头颈癌（21例）和黑色素瘤（21例）。除黑色素瘤患者外，所有患者均接受过先前的化疗。该药物通过静脉注射，在3周周期的第1至5天以120 mg/m²的剂量进行20分钟输注。治疗耐受性良好；唯一显著的副作用是轻度头痛和全身性肌肉骨骼疼痛。在2个周期的治疗后评估疗效。只有1例患者（头颈癌患者）实现了客观部分缓解，持续6周。共有12例患者病情稳定，中位持续时间为15至20周。按照这种给药方案，磷喹酮在这组肿瘤中没有显著的抗肿瘤活性。
